Software - Application
Compare Stocks
4 / 10Stock Comparison
DT vs APM vs DDOG vs CASI
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Software - Application
Biotechnology
DT vs APM vs DDOG vs CASI — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Software - Application | Biotechnology | Software - Application | Biotechnology |
| Market Cap | $12.09B | $5M | $67.18B | $2M |
| Revenue (TTM) | $1.93B | $431K | $3.67B | $27M |
| Net Income (TTM) | $185M | $-7M | $136M | $-49M |
| Gross Margin | 81.6% | -318.7% | 79.9% | 35.8% |
| Operating Margin | 13.0% | -33.5% | -0.7% | -168.0% |
| Forward P/E | 24.0x | — | 88.0x | — |
| Total Debt | $75M | $3M | $1.54B | $22M |
| Cash & Equiv. | $1.02B | $874K | $401M | $13M |
DT vs APM vs DDOG vs CASI — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Dynatrace, Inc. (DT) | 100 | 104.9 | +4.9% |
| Aptorum Group Limit… (APM) | 100 | 2.7 | -97.3% |
| Datadog, Inc. (DDOG) | 100 | 264.8 | +164.8% |
| CASI Pharmaceutical… (CASI) | 100 | 0.9 | -99.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: DT vs APM vs DDOG vs CASI
Each card shows where this stock fits in a portfolio — not just who wins on paper.
DT carries the broadest edge in this set and is the clearest fit for growth exposure and sleep-well-at-night.
- Rev growth 18.7%, EPS growth 205.8%, 3Y rev CAGR 22.3%
- Lower volatility, beta 0.80, Low D/E 2.9%, current ratio 1.40x
- Beta 0.80, current ratio 1.40x
- Better valuation composite
APM is the clearest fit if your priority is income & stability.
- Dividend streak 1 yrs, beta 1.60
DDOG is the #2 pick in this set and the best alternative if long-term compounding is your priority.
- 402.6% 10Y total return vs DT's 69.3%
- 27.7% revenue growth vs APM's -100.0%
- +78.0% vs CASI's -91.2%
CASI is the clearest fit if your priority is dividends.
- 31.1% yield; the other 3 pay no meaningful dividend
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 27.7% revenue growth vs APM's -100.0% | |
| Value | Better valuation composite | |
| Quality / Margins | 9.6% margin vs APM's -16.4% | |
| Stability / Safety | Beta 0.80 vs APM's 1.60, lower leverage | |
| Dividends | 31.1% yield; the other 3 pay no meaningful dividend | |
| Momentum (1Y) | +78.0% vs CASI's -91.2% | |
| Efficiency (ROA) | 4.5% ROA vs CASI's -131.5%, ROIC 9.0% vs -153.0% |
DT vs APM vs DDOG vs CASI — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
DT vs APM vs DDOG vs CASI — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
DT leads in 2 of 6 categories
DDOG leads 1 • APM leads 1 • CASI leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — DT and DDOG each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
DDOG is the larger business by revenue, generating $3.7B annually — 8512.3x APM's $431,378. DT is the more profitable business, keeping 9.6% of every revenue dollar as net income compared to APM's -16.4%. On growth, DDOG holds the edge at +32.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $1.9B | $431,378 | $3.7B | $27M |
| EBITDAEarnings before interest/tax | $276M | -$13M | $73M | -$44M |
| Net IncomeAfter-tax profit | $185M | -$7M | $136M | -$49M |
| Free Cash FlowCash after capex | $466M | -$9M | $1.1B | $0 |
| Gross MarginGross profit ÷ Revenue | +81.6% | -3.2% | +79.9% | +35.8% |
| Operating MarginEBIT ÷ Revenue | +13.0% | -33.5% | -0.7% | -168.0% |
| Net MarginNet income ÷ Revenue | +9.6% | -16.4% | +3.7% | -183.9% |
| FCF MarginFCF ÷ Revenue | +24.1% | -20.8% | +29.4% | -103.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +18.2% | — | +32.2% | -60.5% |
| EPS Growth (YoY)Latest quarter vs prior year | -89.1% | -156.9% | +120.9% | -23.6% |
Valuation Metrics
DT leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
At 25.4x trailing earnings, DT trades at a 96% valuation discount to DDOG's 629.1x P/E. On an enterprise value basis, DT's 49.0x EV/EBITDA is more attractive than DDOG's 874.0x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $12.1B | $5M | $67.2B | $2M |
| Enterprise ValueMkt cap + debt − cash | $11.2B | $7M | $68.3B | $11M |
| Trailing P/EPrice ÷ TTM EPS | 25.39x | -1.08x | 629.10x | -0.06x |
| Forward P/EPrice ÷ next-FY EPS est. | 23.98x | — | 87.97x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 49.01x | — | 874.03x | — |
| Price / SalesMarket cap ÷ Revenue | 7.12x | — | 19.60x | 0.08x |
| Price / BookPrice ÷ Book value/share | 4.68x | 0.39x | 18.38x | 1.25x |
| Price / FCFMarket cap ÷ FCF | 27.91x | — | 67.14x | — |
Profitability & Efficiency
DT leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
DT delivers a 6.7% return on equity — every $100 of shareholder capital generates $7 in annual profit, vs $-3 for CASI. DT carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to CASI's 11.96x. On the Piotroski fundamental quality scale (0–9), DDOG scores 6/9 vs APM's 1/9, reflecting solid financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | +6.7% | -60.2% | +3.8% | -3.0% |
| ROA (TTM)Return on assets | +4.5% | -44.0% | +2.1% | -131.5% |
| ROICReturn on invested capital | +9.0% | -18.3% | -0.8% | -153.0% |
| ROCEReturn on capital employed | +7.3% | -25.0% | -1.0% | -104.6% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 1 | 6 | 2 |
| Debt / EquityFinancial leverage | 0.03x | 0.28x | 0.41x | 11.96x |
| Net DebtTotal debt minus cash | -$942M | $2M | $1.1B | $9M |
| Cash & Equiv.Liquid assets | $1.0B | $874,238 | $401M | $13M |
| Total DebtShort + long-term debt | $75M | $3M | $1.5B | $22M |
| Interest CoverageEBIT ÷ Interest expense | — | -30.72x | 4.03x | -66.88x |
Total Returns (Dividends Reinvested)
DDOG leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DDOG five years ago would be worth $24,418 today (with dividends reinvested), compared to $94 for CASI. Over the past 12 months, DDOG leads with a +78.0% total return vs CASI's -91.2%. The 3-year compound annual growth rate (CAGR) favors DDOG at 33.9% vs CASI's -60.8% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -4.7% | -21.5% | +41.1% | -81.6% |
| 1-Year ReturnPast 12 months | -15.7% | -5.6% | +78.0% | -91.2% |
| 3-Year ReturnCumulative with dividends | -8.2% | -76.9% | +140.3% | -94.0% |
| 5-Year ReturnCumulative with dividends | -13.7% | -96.6% | +144.2% | -99.1% |
| 10-Year ReturnCumulative with dividends | +69.3% | -99.4% | +402.6% | -99.0% |
| CAGR (3Y)Annualised 3-year return | -2.8% | -38.7% | +33.9% | -60.8% |
Risk & Volatility
Evenly matched — DDOG and CASI each lead in 1 of 2 comparable metrics.
Risk & Volatility
CASI is the less volatile stock with a -0.12 beta — it tends to amplify market swings less than APM's 1.60 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DDOG currently trades 93.6% from its 52-week high vs CASI's 4.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.80x | 1.60x | 1.40x | -0.12x |
| 52-Week HighHighest price in past year | $57.55 | $4.47 | $201.69 | $3.09 |
| 52-Week LowLowest price in past year | $31.64 | $0.65 | $98.01 | $0.05 |
| % of 52W HighCurrent price vs 52-week peak | +70.1% | +18.8% | +93.6% | +4.9% |
| RSI (14)Momentum oscillator 0–100 | 58.8 | 45.2 | 66.5 | 24.2 |
| Avg Volume (50D)Average daily shares traded | 6.8M | 51K | 5.0M | 146K |
Analyst Outlook
APM leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: DT as "Buy", DDOG as "Buy". Consensus price targets imply 23.4% upside for DT (target: $50) vs -7.5% for DDOG (target: $175). CASI is the only dividend payer here at 31.10% yield — a key consideration for income-focused portfolios.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — | Buy | — |
| Price TargetConsensus 12-month target | $49.81 | — | $174.63 | — |
| # AnalystsCovering analysts | 34 | — | 47 | — |
| Dividend YieldAnnual dividend ÷ price | — | — | — | +31.1% |
| Dividend StreakConsecutive years of raises | — | 1 | — | 0 |
| Dividend / ShareAnnual DPS | — | — | — | $0.05 |
| Buyback YieldShare repurchases ÷ mkt cap | +1.4% | 0.0% | 0.0% | 0.0% |
DT leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). DDOG leads in 1 (Total Returns). 2 tied.
DT vs APM vs DDOG vs CASI: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is DT or APM or DDOG or CASI a better buy right now?
For growth investors, Datadog, Inc.
(DDOG) is the stronger pick with 27. 7% revenue growth year-over-year, versus -100. 0% for Aptorum Group Limited (APM). Dynatrace, Inc. (DT) offers the better valuation at 25. 4x trailing P/E (24. 0x forward), making it the more compelling value choice. Analysts rate Dynatrace, Inc. (DT) a "Buy" — based on 34 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — DT or APM or DDOG or CASI?
On trailing P/E, Dynatrace, Inc.
(DT) is the cheapest at 25. 4x versus Datadog, Inc. at 629. 1x. On forward P/E, Dynatrace, Inc. is actually cheaper at 24. 0x.
03Which is the better long-term investment — DT or APM or DDOG or CASI?
Over the past 5 years, Datadog, Inc.
(DDOG) delivered a total return of +144. 2%, compared to -99. 1% for CASI Pharmaceuticals, Inc. (CASI). Over 10 years, the gap is even starker: DDOG returned +402. 6% versus APM's -99. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — DT or APM or DDOG or CASI?
By beta (market sensitivity over 5 years), CASI Pharmaceuticals, Inc.
(CASI) is the lower-risk stock at -0. 12β versus Aptorum Group Limited's 1. 60β — meaning APM is approximately -1402% more volatile than CASI relative to the S&P 500. On balance sheet safety, Dynatrace, Inc. (DT) carries a lower debt/equity ratio of 3% versus 12% for CASI Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — DT or APM or DDOG or CASI?
By revenue growth (latest reported year), Datadog, Inc.
(DDOG) is pulling ahead at 27. 7% versus -100. 0% for Aptorum Group Limited (APM). On earnings-per-share growth, the picture is similar: Dynatrace, Inc. grew EPS 205. 8% year-over-year, compared to -41. 2% for Datadog, Inc.. Over a 3-year CAGR, DDOG leads at 26. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — DT or APM or DDOG or CASI?
Dynatrace, Inc.
(DT) is the more profitable company, earning 28. 5% net margin versus -1644. 3% for Aptorum Group Limited — meaning it keeps 28. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DT leads at 10. 6% versus -33. 5% for APM. At the gross margin level — before operating expenses — DT leads at 81. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is DT or APM or DDOG or CASI more undervalued right now?
On forward earnings alone, Dynatrace, Inc.
(DT) trades at 24. 0x forward P/E versus 88. 0x for Datadog, Inc. — 64. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DT: 23. 4% to $49. 81.
08Which pays a better dividend — DT or APM or DDOG or CASI?
In this comparison, CASI (31.
1% yield) pays a dividend. DT, APM, DDOG do not pay a meaningful dividend and should not be held primarily for income.
09Is DT or APM or DDOG or CASI better for a retirement portfolio?
For long-horizon retirement investors, CASI Pharmaceuticals, Inc.
(CASI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 12), 31. 1% yield). Aptorum Group Limited (APM) carries a higher beta of 1. 60 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CASI: -99. 0%, APM: -99. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between DT and APM and DDOG and CASI?
These companies operate in different sectors (DT (Technology) and APM (Healthcare) and DDOG (Technology) and CASI (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: DT is a mid-cap high-growth stock; APM is a small-cap quality compounder stock; DDOG is a mid-cap high-growth stock; CASI is a small-cap income-oriented stock. CASI pays a dividend while DT, APM, DDOG do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.